{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-079997","form_type":"8-K/A","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.658572+00:00","generated_at":"2026-06-26T21:29:36.423766+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adagio discloses additional compensation for Interim CEO Hering: $510K base, $7.5K monthly stipend","bullets":["David Hering appointed Interim CEO on Feb 23, 2022 after Tillman Gerngross resigned as CEO and board member.","Compensation approved Mar 18: base salary increased to $510,000 (eff. Feb 23) plus $7,500 monthly stipend during interim role.","2022 target bonus uses blended rate: 60% at assumed $600K salary for Interim CEO time, 40% at $410K for COO time.","Tom Heyman reclassified from Class II to Class III director to rebalance board classes following Gerngross resignation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-079997","json":"https://secwatch.observer/filing/0001193125-22-079997.json","markdown":"https://secwatch.observer/filing/0001193125-22-079997.md","text":"https://secwatch.observer/filing/0001193125-22-079997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522079997/0001193125-22-079997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522079997/d285779d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:29:36.423766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4959d137ac","claim":"David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..","evidence_excerpt":"Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522079997/0001193125-22-079997-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8595896045","claim":"Tillman U. Gerngross resigned as Chief Executive Officer and President at Invivyd, Inc..","evidence_excerpt":"On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522079997/0001193125-22-079997-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}